JP2019510082A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510082A5
JP2019510082A5 JP2018566649A JP2018566649A JP2019510082A5 JP 2019510082 A5 JP2019510082 A5 JP 2019510082A5 JP 2018566649 A JP2018566649 A JP 2018566649A JP 2018566649 A JP2018566649 A JP 2018566649A JP 2019510082 A5 JP2019510082 A5 JP 2019510082A5
Authority
JP
Japan
Prior art keywords
independently
represent
optionally substituted
halo
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018566649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510082A (ja
JP7046842B2 (ja
Filing date
Publication date
Priority claimed from GBGB1603886.1A external-priority patent/GB201603886D0/en
Priority claimed from GBGB1701928.2A external-priority patent/GB201701928D0/en
Application filed filed Critical
Priority claimed from PCT/GB2017/050605 external-priority patent/WO2017153737A1/en
Publication of JP2019510082A publication Critical patent/JP2019510082A/ja
Publication of JP2019510082A5 publication Critical patent/JP2019510082A5/ja
Application granted granted Critical
Publication of JP7046842B2 publication Critical patent/JP7046842B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018566649A 2016-03-07 2017-03-07 高血糖症の治療のための化合物 Expired - Fee Related JP7046842B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1603886.1A GB201603886D0 (en) 2016-03-07 2016-03-07 Compounds for the treatment of type 2 diabetes
GB1603886.1 2016-03-07
GB1701928.2 2017-02-06
GBGB1701928.2A GB201701928D0 (en) 2017-02-06 2017-02-06 Compounds for the treatment of hyperglycaemia
PCT/GB2017/050605 WO2017153737A1 (en) 2016-03-07 2017-03-07 Compounds for the treatment of hyperglycaemia

Publications (3)

Publication Number Publication Date
JP2019510082A JP2019510082A (ja) 2019-04-11
JP2019510082A5 true JP2019510082A5 (https=) 2020-04-02
JP7046842B2 JP7046842B2 (ja) 2022-04-04

Family

ID=58489714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566649A Expired - Fee Related JP7046842B2 (ja) 2016-03-07 2017-03-07 高血糖症の治療のための化合物

Country Status (5)

Country Link
US (1) US20190119196A1 (https=)
EP (1) EP3426239A1 (https=)
JP (1) JP7046842B2 (https=)
KR (1) KR20180117696A (https=)
WO (1) WO2017153737A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
GB201714736D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) * 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
EP4651867A1 (en) 2023-01-20 2025-11-26 Atrogi AB Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202304661D0 (en) * 2023-03-29 2023-05-10 Atrogi Ab New compounds and medical uses thereof
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814350A (en) * 1986-09-10 1989-03-21 American Cyanamid Company Method of treating diabetes with 5-[1-hydroxy-2-(isopropylamino)ethyl]anthranilonitrile
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
WO2005025570A1 (en) * 2003-09-15 2005-03-24 Diamedica Inc. Use of antagonists of hepatic sympathetic nerve activity
US20050250944A1 (en) * 2004-05-04 2005-11-10 Jian Chen Synthesis and uses of synephrine derivatives
EP1781303A4 (en) * 2004-06-30 2008-07-02 Combinatorx Inc METHOD AND REAGENTS FOR THE TREATMENT OF METABOLISM DISEASES
WO2010016939A1 (en) 2008-08-08 2010-02-11 The Trustees Of Columbia University In The City Of New York Hypoglycemic dihydropyridones
US9784726B2 (en) * 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
PE20180187A1 (es) * 2015-03-03 2018-01-23 Saniona As Formulacion de combinacion de tesofensina y betabloqueante

Similar Documents

Publication Publication Date Title
JP2019510082A5 (https=)
CN116249683A8 (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
JP2016503797A5 (https=)
JP2019517487A5 (https=)
JP2017523169A5 (https=)
JP2013537203A5 (https=)
RU2019100164A (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
JP2020502047A5 (https=)
JP2016505637A5 (https=)
JP2014511891A5 (https=)
JP2015500843A5 (https=)
JP2020534264A5 (https=)
JP2018537535A5 (https=)
JP2010031025A5 (https=)
JP2016505512A5 (https=)
JP2020507589A5 (https=)
JP2016513130A5 (https=)
JP2018135343A5 (https=)
JP2016510326A5 (https=)
JP2016531126A5 (https=)
JP2016505614A5 (https=)
JP2020533352A5 (https=)
JP2019531279A5 (https=)
JP2019527233A5 (https=)
JP2019520344A5 (https=)